middle.news
Neurizon Accelerates ALS Trial Results After Fastest Ever HEALEY Enrolment
9:25am on Friday 17th of July, 2026 AEST
•
Biotechnology
Read Story
Neurizon Accelerates ALS Trial Results After Fastest Ever HEALEY Enrolment
9:25am on Friday 17th of July, 2026 AEST
Key Points
250 participants enrolled in record time for Regimen I
Topline efficacy and safety results now expected late Q2 2027
Trial expansion from 160 to 240 participants amid strong recruitment
Completion reduces execution risk for NUZ-001 program
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE